

COMPANY OF THE YEAR



Frost & Sullivan analysts independently evaluated key factors according to the criteria identified below:

Visionary Innovation and Performance

- Criterion 1: Addressing Unmet Needs
- Criterion 2: Visionary Scenarios through Mega Trends
- Criterion 3: Implementation of Best Practices
- Criterion 4: Blue Ocean Strategy
- Criterion 5: Financial Performance

Customer Impact

- Criterion 1: Price/Performance Value
- Criterion 2: Customer Purchase Experience
- Criterion 3: Customer Ownership Experience
- Criterion 4: Customer Service Experience
- Criterion 5: Brand Equity

MEDEZE GROUP IS A LEADER IN STEM CELL BANKING AND AN INNOVATOR IN ORGAN AND TISSUE CREATION USING ADVANCED STEM CELL TECHNOLOGIES. WITH A STEADFAST MISSION TO LEAD THE INDUSTRY THROUGH INNOVATION AND EXCELLENCE, THE COMPANY SETS THE BENCHMARK FOR CARE STANDARDS AND GLOBAL ADVANCEMENT IN STEM CELL RESEARCH.

**- UNMESH LAL
PHARMACEUTICAL,
RESEARCH DIRECTOR**

To receive the Company of the Year Award requires a company to demonstrate excellence in growth, innovation, and leadership. This excellence typically translates into superior performance in three key areas—demand generation, brand development, and competitive positioning—that serve as the foundation of a company’s future success and prepare it to deliver on the 2 factors that define the Company of the Year Award.



Medeze Group leads Southeast Asia's stem cell banking sector, focusing on technological innovation and comprehensive services. Utilizing cutting-edge technologies like quantum machines and therapies such as hair follicle restoration and artificial cornea implants, Medeze enhances stem cell treatments for longevity and wellness. The company emphasizes superior stem cell quality and personalized care, addressing immediate and long-term health needs. Expanding regionally, Medeze aims to make advanced stem cell banking more accessible, promoting well-being.

With its strong overall performance, Medeze earns Frost & Sullivan’s 2024 SEA Company of the Year Award in the stem cell banking and longevity industry.